Drug
Peginterferon alpha-2a (PegIFN alpha-2a)
Peginterferon alpha-2a (PegIFN alpha-2a) is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_3
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 32 (100.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_3
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
NCT01289782
completedphase_3
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
NCT01281839
Clinical Trials (2)
Showing 2 of 2 trials
NCT01289782Phase 3
An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
NCT01281839Phase 3
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2